These limitations underscore the potential advantage of targeting the upstream GH–GHR axis, which can simultaneously reduce circulating IGF1 levels, suppress IGF1R signaling in the TME, and attenuate tumor-promoting pathways [10,21,56]. The gene discussed is GH1; the disease is neoplasm.